Michael W. Spellman
Profile
Michael W.
Spellman is Senior Vice President of Pharmaceutical Development for Dynogen Pharmaceuticals, Inc. Prior to joining Dynogen, he was Vice President of Process Development for Millennium Pharmaceuticals.
Previously, Dr. Spellman was Vice President of Preclinical Development for Coulter Pharmaceuticals.
Before that, he worked at Genentech, Inc. Dr.Spellman has over 20 years of drug development experience with responsibility in areas of analytical development, preclinical development, quality assurance, quality control, and process development for the biotechnology companies.
He received a Bachelor's degree in Natural Science from Assumption College and a PhD in Biochemistry from Michigan State University.
Former positions of Michael W. Spellman
| Companies | Position | End |
|---|---|---|
Dynogen Pharmaceuticals, Inc.
 Dynogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dynogen Pharmaceuticals, Inc. develops and manufactures drugs. The company makes drugs for genitourinary and gastrointestinal disorders. It also makes drugs for constipation, Irritable Bowel Syndrome and overactive bladder. Dynogen Pharmaceuticals was founded by Lee R. Brettman in 2002 and is located in Waltham, MA. | Corporate Officer/Principal | 2009-11-12 |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Michael W. Spellman
| Michigan State University | Doctorate Degree |
| Assumption College | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
Dynogen Pharmaceuticals, Inc.
Dynogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dynogen Pharmaceuticals, Inc. develops and manufactures drugs. The company makes drugs for genitourinary and gastrointestinal disorders. It also makes drugs for constipation, Irritable Bowel Syndrome and overactive bladder. Dynogen Pharmaceuticals was founded by Lee R. Brettman in 2002 and is located in Waltham, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
- Stock Market
- Insiders
- Michael W. Spellman
